Inorbit discovers drugs for the treatment of NASH. Its lead project, the FXR agonist IOT022, shows great in vivo efficacy and drug like properties. It is ready for IND characterisation studies, starting Q1 2019, preparing it for testing in man.
It’s easy to create a pitch using our online form. Your pitch can be in front of our 195,407 investors before you know it.
It’s free to join the world’s largest angel investment community. You’ll then have full access to this pitch (and all the others) and be able to connect with entrepreneurs.